PSMA radioligand therapy (PRLT) of metastatic castration-resistant prostate cancer: first results using the PSMA Inhibitor 617

被引：0
|
作者：
Kulkarni, Harshad [1 ]
Singh, Aviral [1 ]
Niepsch, Karin [1 ]
Schuchardt, Christiane [1 ]
Baum, Richard [1 ]
机构：
[1] Zent Klin Bad Berka, THERANOST Ctr Mol Radiotherapy & Mol Imaging PET, Bad Berka, Germany
来源：
JOURNAL OF NUCLEAR MEDICINE | 2016年 / 57卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
139
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Treatment of castration-resistant metastatic prostate cancer with [177Lu]PSMA radioligand
    Sundset, Rune
    Haugnes, Hege Sagstuen
    Perez, Alexander
    Engelsen, Ola
    Fosseide, Ida H. H.
    Castillejo, Miguel J.
    Bogsrud, Trond Velde
    TIDSSKRIFT FOR DEN NORSKE LAEGEFORENING, 2024, 144 (09)
  • [22] Lu-177 PSMA Radioligand Therapy as Salvage Treatment in Metastatic Castration-Resistant Prostate Cancer
    Kulkarni, H. R.
    Singh, A.
    Schuchardt, C.
    Langbein, T.
    Zhang, J.
    Baum, R. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S287 - S288
  • [23] Re: Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
    Hadaschik, Boris
    Herrmann, Ken
    EUROPEAN UROLOGY, 2021, 80 (04) : 520 - 521
  • [24] Cost Utility Analysis of 177Lu-PSMA-617 Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer (mCRPC) in Germany
    Stargardt, T.
    Brinkmann, C.
    Baum, R. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S827 - S827
  • [25] Comment on, 177Lu-PSMA-617 in metastatic, castration-resistant prostate cancer"
    Radtke, Jan Philipp
    Albers, Peter
    Giesel, Frederik Lars
    AKTUELLE UROLOGIE, 2022, 53 (02)
  • [26] Re: Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
    Sartor, O.
    de Bono, J.
    Chi, K. N.
    Fizazi, K.
    Herrmann, K.
    Rahbar, K.
    Tagawa, S. T.
    Nordquist, L. T.
    Vaishampayan, N.
    El-Haddad, G.
    Park, C. H.
    Beer, T. M.
    Armour, A.
    Perez-Contreras, W. J.
    DeSilvio, M.
    Kpamegan, E.
    Gericke, G.
    Messmann, R. A.
    Morris, M. J.
    Krause, B. J.
    JOURNAL OF UROLOGY, 2022, 207 (02): : 467 - 468
  • [27] 68Ga-PSMA PET/CT for monitoring response to 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
    Heinzel, Alexander
    Boghos, Dima
    Mottaghy, Felix M.
    Gaertner, Florian
    Essler, Markus
    von Mallek, Dirk
    Ahmadzadehfar, Hojjat
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (05) : 1054 - 1062
  • [28] 68Ga-PSMA PET/CT for monitoring response to 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
    Alexander Heinzel
    Dima Boghos
    Felix M. Mottaghy
    Florian Gaertner
    Markus Essler
    Dirk von Mallek
    Hojjat Ahmadzadehfar
    European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46 : 1054 - 1062
  • [29] Combined 177Lu-PSMA-617 PRLT and abiraterone acetate versus 177Lu-PSMA-617 PRLT monotherapy in metastatic castration-resistant prostate cancer: An observational study comparing the response and durability
    Suman, Sonam
    Parghane, Rahul V.
    Joshi, Amit
    Prabhash, Kumar
    Talole, Sanjay
    Basu, Sandip
    PROSTATE, 2021, 81 (15): : 1225 - 1234
  • [30] 177Lu-PSMA-I&T PSMA Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer:FirstClinical trialin Asia
    Bu, Ting
    Zhang, Pengjun
    Zang, Shiming
    Zhang, Lulu
    Wang, Feng
    JOURNAL OF NUCLEAR MEDICINE, 2019, 60
12345